Floatz logo

Olaparib

Refractory Peripheral T-Cell Lymphoma

National Cancer Centre, SingaporeSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Refractory Peripheral T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Folic Acid
Acrotech Biopharma Inc.
Phase 2B
Cobalamin
Acrotech Biopharma Inc.
Phase 2B

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →